NasdaqGM:NERV

Stock Analysis Report

Executive Summary

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases.

Snowflake

Fundamentals

Excellent balance sheet with moderate growth potential.

Risks

  • Minerva Neurosciences has significant price volatility in the past 3 months.

Share Price & News

How has Minerva Neurosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.3%

NasdaqGM:NERV

-0.5%

US Biotechs

-0.02%

US Market


1 Year Return

-31.0%

NasdaqGM:NERV

-11.3%

US Biotechs

1.6%

US Market

NERV underperformed the Biotechs industry which returned -10.2% over the past year.

NERV underperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

NERVIndustryMarket
7 Day4.3%-0.5%-0.02%
30 Day21.2%-2.1%2.7%
90 Day99.1%-1.9%1.4%
1 Year-31.0%-31.0%-10.6%-11.3%3.8%1.6%
3 Year-41.1%-41.1%4.6%1.1%45.2%35.8%
5 Year43.4%43.4%1.9%-3.0%61.8%44.1%

Price Volatility Vs. Market

How volatile is Minerva Neurosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Minerva Neurosciences undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Minerva Neurosciences's share price is below the future cash flow value, and at a moderate discount (> 20%).

Minerva Neurosciences's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Minerva Neurosciences is loss making, we can't compare its value to the US Biotechs industry average.

Minerva Neurosciences is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Minerva Neurosciences, we can't assess if its growth is good value.


Price Based on Value of Assets

Minerva Neurosciences is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Minerva Neurosciences expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

47.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Minerva Neurosciences is high growth as no revenue estimate data is available.

Minerva Neurosciences's earnings are expected to grow significantly at over 20% yearly.

Unable to compare Minerva Neurosciences's revenue growth to the United States of America market average as no estimate data is available.

Minerva Neurosciences's earnings growth is expected to exceed the United States of America market average.

Minerva Neurosciences's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Minerva Neurosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Minerva Neurosciences performed over the past 5 years?

-1.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Minerva Neurosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Minerva Neurosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Minerva Neurosciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Minerva Neurosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Minerva Neurosciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Minerva Neurosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Minerva Neurosciences's financial position?


Financial Position Analysis

Minerva Neurosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Minerva Neurosciences's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Minerva Neurosciences has no debt.

Minerva Neurosciences has no debt compared to 5 years ago when it was 11.4%.


Balance Sheet

Low level of unsold assets.

Minerva Neurosciences has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Minerva Neurosciences has sufficient cash runway for 1.8 years based on current free cash flow.

Minerva Neurosciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 23.8% each year.


Next Steps

Dividend

What is Minerva Neurosciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Minerva Neurosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Minerva Neurosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Minerva Neurosciences has not reported any payouts.

Unable to verify if Minerva Neurosciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Minerva Neurosciences has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Minerva Neurosciences's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Minerva Neurosciences's salary, the management and board of directors tenure and is there insider trading?

4.5yrs

Average management tenure


CEO

Rémy Luthringer (58yo)

4.8yrs

Tenure

US$3,910,245

Compensation

Dr. Rémy Luthringer serves as a Clinical Advisor to the Medicxi investment team and a Member of the Co-Founding team at Medicxi Ventures (UK) LLP. He has played an active role in several Index Ventures. He ...


CEO Compensation Analysis

Rémy's remuneration is higher than average for companies of similar size in United States of America.

Rémy's compensation has increased whilst company is loss making.


Management Age and Tenure

4.5yrs

Average Tenure

58yo

Average Age

The tenure for the Minerva Neurosciences management team is about average.


Board Age and Tenure

1.8yrs

Average Tenure

61yo

Average Age

The average tenure for the Minerva Neurosciences board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Minerva Neurosciences individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$19,25001 Jul 19
William Doyle
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares3,500
Max PriceUS$5.50
BuyUS$53,70027 Jun 19
G. van Heek
EntityIndividual
Shares10,000
Max PriceUS$5.37
BuyUS$5,25027 Jun 19
Jeryl Hilleman
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,000
Max PriceUS$5.25
BuyUS$56,00027 Jun 19
Hans Hasler
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$5.60
BuyUS$55,50027 Jun 19
David Kupfer
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$5.55
SellUS$1,166,79426 Jun 19
Index Ventures
EntityCompany
Shares194,000
Max PriceUS$6.01
SellUS$488,91121 Jun 19
Index Ventures
EntityCompany
Shares110,818
Max PriceUS$4.44
SellUS$470,73019 Jun 19
Index Ventures
EntityCompany
Shares105,918
Max PriceUS$4.45
SellUS$250,20818 Jun 19
Index Ventures
EntityCompany
Shares56,243
Max PriceUS$4.45
SellUS$352,44217 Jun 19
Index Ventures
EntityCompany
Shares78,179
Max PriceUS$4.51
SellUS$281,34313 Jun 19
Index Ventures
EntityCompany
Shares60,051
Max PriceUS$4.78
SellUS$137,89621 May 19
Index Ventures
EntityCompany
Shares22,918
Max PriceUS$6.08
SellUS$898,16116 May 19
Index Ventures
EntityCompany
Shares134,828
Max PriceUS$7.05
BuyUS$13,00026 Dec 18
William Doyle
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares2,000
Max PriceUS$6.50
SellUS$24,81113 Dec 18
Richard Russell
EntityIndividual
Role
President
President
Shares3,117
Max PriceUS$7.96
BuyUS$47,80012 Dec 18
William Doyle
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares6,000
Max PriceUS$8.00
BuyUS$16,40021 Nov 18
William Doyle
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares2,000
Max PriceUS$8.20
BuyUS$6,00015 Oct 18
William Doyle
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares600
Max PriceUS$10.00
SellUS$190,74703 Oct 18
Index Ventures
EntityCompany
Shares15,444
Max PriceUS$12.35
SellUS$834,61801 Oct 18
Index Ventures
EntityCompany
Shares66,273
Max PriceUS$12.62

Ownership Breakdown


Management Team

  • Geoff Race (58yo)

    Executive VP

    • Tenure: 5.3yrs
    • Compensation: US$1.53m
  • William Boni (67yo)

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 4.1yrs
  • Fred Ahlholm (53yo)

    Senior VP & Chief Accounting Officer

    • Tenure: 5.2yrs
    • Compensation: US$845.36k
  • Rémy Luthringer (58yo)

    Executive Chairman & CEO

    • Tenure: 4.8yrs
    • Compensation: US$3.91m
  • Rick Russell (55yo)

    President

    • Tenure: 1.8yrs
    • Compensation: US$2.22m
  • Joe Reilly (44yo)

    Senior VP & COO

    • Tenure: 5.2yrs
    • Compensation: US$1.49m
  • Devin Smith (51yo)

    Senior VP

    • Tenure: 1.2yrs
    • Compensation: US$2.24m
  • Michael Davidson (69yo)

    Chief Medical Officer

    • Tenure: 2.8yrs
    • Compensation: US$2.84m
  • Jay Saoud (60yo)

    Senior VP and Head of Research & Development

    • Tenure: 0yrs

Board Members

  • Bill Doyle (57yo)

    Lead Independent Director

    • Tenure: 1.6yrs
    • Compensation: US$272.53k
  • Jeri Hilleman (61yo)

    Independent Director

    • Tenure: 1.2yrs
    • Compensation: US$241.15k
  • Hans Hasler (63yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$153.13k
  • David Kupfer (78yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$149.63k
  • Rémy Luthringer (58yo)

    Executive Chairman & CEO

    • Tenure: 4.8yrs
    • Compensation: US$3.91m
  • Jan van Heek (70yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: US$156.88k
  • Fouzia Laghrissi-Thode (56yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$153.26k

Company Information

Minerva Neurosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Minerva Neurosciences, Inc.
  • Ticker: NERV
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$328.594m
  • Shares outstanding: 39.03m
  • Website: https://www.minervaneurosciences.com

Number of Employees


Location

  • Minerva Neurosciences, Inc.
  • 1601 Trapelo Road
  • Suite 286
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NERVNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2014
4MNDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2014

Biography

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system di ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 00:25
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.